NO20074843L - Nye salter av 6-heterocyklylsubstituerte heksahydrofenantridinderivater - Google Patents

Nye salter av 6-heterocyklylsubstituerte heksahydrofenantridinderivater

Info

Publication number
NO20074843L
NO20074843L NO20074843A NO20074843A NO20074843L NO 20074843 L NO20074843 L NO 20074843L NO 20074843 A NO20074843 A NO 20074843A NO 20074843 A NO20074843 A NO 20074843A NO 20074843 L NO20074843 L NO 20074843L
Authority
NO
Norway
Prior art keywords
heterocyclyl
new salts
derivatives
substituted
substituted hexahydrophenanthridine
Prior art date
Application number
NO20074843A
Other languages
English (en)
Other versions
NO339416B1 (no
Inventor
Rolf-Peter Hummel
Christian Scheufler
Ulrich Kautz
Matthias Webel
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of NO20074843L publication Critical patent/NO20074843L/no
Publication of NO339416B1 publication Critical patent/NO339416B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)

Abstract

Oppfinnelsen vedrører salter av 6-heteroarylsubstituerte heksahydrofenantridin PDE4-hemmende forbindelser, som kan anvendes i den farmasøytiske industri for fremstillingen av farmasøytiske sammensetninger for anvendelse, f.eks. i behandlingen av luftveislidelser. ?? ?? ?? ?? - 1 -
NO20074843A 2005-03-02 2007-09-24 Nye salter av 6-heterocyklylsubstituerte heksahydrofenantridinderivater NO339416B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101619 2005-03-02
EP05108442 2005-09-14
PCT/EP2006/060377 WO2006092422A1 (en) 2005-03-02 2006-03-01 Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives

Publications (2)

Publication Number Publication Date
NO20074843L true NO20074843L (no) 2007-09-24
NO339416B1 NO339416B1 (no) 2016-12-12

Family

ID=36295528

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074843A NO339416B1 (no) 2005-03-02 2007-09-24 Nye salter av 6-heterocyklylsubstituerte heksahydrofenantridinderivater

Country Status (24)

Country Link
US (4) US7718668B2 (no)
EP (3) EP1856093B1 (no)
JP (2) JP5478828B2 (no)
KR (2) KR101352687B1 (no)
AT (1) ATE450524T1 (no)
AU (1) AU2006219867B2 (no)
BR (1) BRPI0607645A2 (no)
CA (1) CA2598860C (no)
CY (1) CY1109753T1 (no)
DE (1) DE602006010824D1 (no)
DK (1) DK1856093T3 (no)
EA (1) EA015376B1 (no)
ES (2) ES2337083T3 (no)
HR (1) HRP20100086T1 (no)
IL (2) IL185276A (no)
ME (1) ME01172B (no)
MX (1) MX2007010400A (no)
NO (1) NO339416B1 (no)
NZ (2) NZ560268A (no)
PL (1) PL1856093T3 (no)
PT (1) PT1856093E (no)
RS (1) RS51345B (no)
SI (1) SI1856093T1 (no)
WO (1) WO2006092422A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496459C (en) 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
PL2589599T4 (pl) 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
MXPA06009892A (es) * 2004-03-10 2007-03-01 Altana Pharma Ag Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4).
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.
MEP8509A (en) 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
SMT201800664T1 (it) 2011-12-15 2019-01-11 Alkermes Pharma Ireland Ltd Samidorphan (alks 33) in combinazione con buprenorfina per il trattamento di disturbi depressivi
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
EP3503892A1 (en) 2016-08-26 2019-07-03 Takeda GmbH Treatment of nonalcoholic fatty liver disease
CN110573148A (zh) 2017-03-16 2019-12-13 武田有限公司 特发性肺纤维化的治疗

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
EE03523B1 (et) 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
CA2250569C (en) * 1996-03-26 2005-05-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel phenanthridines substituted in the 6 position
US6127378A (en) * 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
DK0937074T3 (da) 1996-11-11 2003-06-23 Altana Pharma Ag Benzonaphthyridiner som bronkiale terapeutiske midler
SI0968211T1 (en) 1997-03-07 2004-02-29 Altana Pharma Ag Tetrazole derivatives
AU8106598A (en) 1997-06-03 1998-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
PT1000034E (pt) 1997-07-25 2003-02-28 Altana Pharma Ag 6-alquilfenantridinas substituidas
PT1000035E (pt) 1997-07-25 2003-04-30 Altana Pharma Ag 6-fenilfenantridinas substituidas
AU753615B2 (en) 1997-07-25 2002-10-24 Altana Pharma Ag Novel tetrazole derivatives
CA2330738A1 (en) 1998-05-05 1999-11-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel n-oxides of benzonaphthyridines
SI1109810T1 (en) 1998-08-31 2004-12-31 Altana Pharma Ag Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity
EE05105B1 (et) 1999-01-15 2008-12-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenlfenantridiinid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
EP1147103B1 (en) 1999-01-15 2005-05-04 ALTANA Pharma AG Phenantrhridine-n-oxides with pde-iv inhibiting activity
ATE356810T1 (de) 1999-01-15 2007-04-15 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
AU2107700A (en) 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity
DE60025327T2 (de) 1999-01-15 2006-08-24 Altana Pharma Ag 6-arylphenanthridine mit pde-iv hemmender wirkung
WO2001051470A1 (en) 2000-01-11 2001-07-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides
AU2001239550A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
SI1303506T1 (en) * 2000-07-14 2005-06-30 Altana Pharma Ag 6-heteroarylphenanthridines
AU2001267589A1 (en) 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
WO2002005616A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
US6936622B2 (en) 2001-02-21 2005-08-30 Altana Pharma Ag 6-phenylbenzonaphthyridines
AU2003263216A1 (en) 2002-08-17 2004-03-11 Nycomed Gmbh Benzonaphthyridines with PDE 3/4 inhibiting activity
CA2495597A1 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
CA2496459C (en) 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
PL2589599T4 (pl) * 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
AR049419A1 (es) 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
AU2005220034A1 (en) 2004-03-09 2005-09-15 Nycomed Gmbh Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
BRPI0508471A8 (pt) 2004-03-10 2019-01-15 Altana Pharma Ag compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
MXPA06009892A (es) 2004-03-10 2007-03-01 Altana Pharma Ag Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4).
CA2558390A1 (en) 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.

Also Published As

Publication number Publication date
DK1856093T3 (da) 2010-03-15
ATE450524T1 (de) 2009-12-15
EP2295423B1 (en) 2013-10-02
CA2598860C (en) 2017-01-17
EP2189454A1 (en) 2010-05-26
NO339416B1 (no) 2016-12-12
US20100190818A1 (en) 2010-07-29
AU2006219867A1 (en) 2006-09-08
HRP20100086T1 (hr) 2010-04-30
EA200701817A1 (ru) 2008-02-28
RS51345B (sr) 2011-02-28
CY1109753T1 (el) 2014-09-10
JP2014040482A (ja) 2014-03-06
KR101421914B1 (ko) 2014-07-22
US8829189B2 (en) 2014-09-09
IL185276A0 (en) 2008-02-09
US20130096152A1 (en) 2013-04-18
NZ560268A (en) 2010-12-24
EP1856093B1 (en) 2009-12-02
DE602006010824D1 (de) 2010-01-14
CA2598860A1 (en) 2006-09-08
KR101352687B1 (ko) 2014-02-17
EP1856093A1 (en) 2007-11-21
ME01172B (me) 2013-03-20
US20140039001A1 (en) 2014-02-06
WO2006092422A1 (en) 2006-09-08
EP2295423A1 (en) 2011-03-16
PT1856093E (pt) 2010-02-08
EA015376B1 (ru) 2011-08-30
NZ589278A (en) 2012-04-27
KR20070107157A (ko) 2007-11-06
JP5478828B2 (ja) 2014-04-23
US20080194587A1 (en) 2008-08-14
IL227565A (en) 2015-05-31
IL185276A (en) 2013-10-31
ES2337083T3 (es) 2010-04-20
SI1856093T1 (sl) 2010-03-31
PL1856093T3 (pl) 2010-05-31
ES2440590T3 (es) 2014-01-29
US8754218B2 (en) 2014-06-17
KR20130108475A (ko) 2013-10-02
AU2006219867B2 (en) 2012-09-13
JP2008531655A (ja) 2008-08-14
US8354535B2 (en) 2013-01-15
BRPI0607645A2 (pt) 2009-09-22
MX2007010400A (es) 2008-01-11
US7718668B2 (en) 2010-05-18
EP2189454B1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
IL227565A (en) Salts of hexahydropananthridine preserved in position 5 of the heterocyclic group and pharmaceutical preparations containing them
NO20083726L (no) Spiroindolinon derivater
DK1881967T3 (da) Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
EA200870262A1 (ru) Способ получения оптических активных хиральных аминов
GB0601744D0 (en) Organic compounds
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2009065922A3 (de) Organische verbindungen
BR112012011328A2 (pt) inibidores de akt
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
ATE552256T1 (de) Neuartige form von tiotropium-bromid und herstellungsverfahren dafür
CY1111954T1 (el) Παραγωγα τετραϋδροναφθαλινιου, μεθοδοι για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδη
EP2274295A4 (en) 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
EP2374799A4 (en) PROCESS FOR PREPARING 4- (1-HYDROXY-1-METHYLETHYL) -2-PROPYLIMIDAZOLE-5-CARBOXYLATE
MA28635B1 (fr) Methode de production de derives de 1, 4-diphenylazetidinone
DE502007003531D1 (de) Verfahren zum herstellen von alkylaniliden aus halogenbenzolderivaten
ATE522515T1 (de) Modulatoren der dopamin-neurotransmission
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
WO2009065921A3 (de) Organischeverbindungen
GEP20094745B (en) Novel naphthalenic derivatives, method for the preparation thereof, and pharmaceutical compositions containing same
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе
IT1391259B1 (it) Derivati 1,3-imidazolidinici e loro utilizzo per la produzione di carbapenem

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

MM1K Lapsed by not paying the annual fees